Research progress of the mechanism of rituximab in the treatment of focal segmental glomerulosclerosis
10.3969/j.issn.1674-8115.2020.05.023
- VernacularTitle: 利妥昔单抗治疗局灶节段性肾小球硬化症机制的研究进展
- Author:
Yin-Hong JI
1
Author Information
1. Department of Nephrology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine
- Publication Type:Journal Article
- Keywords:
Focal segmental glomerulosclerosis (FSGS);
Rituximab (RTX);
Sphingomyelin phosphodiesterase acid-like 3b (SMPDL-3b)
- From:
Journal of Shanghai Jiaotong University(Medical Science)
2020;40(5):693-697
- CountryChina
- Language:Chinese
-
Abstract:
Rituximab (RTX), as a monoclonal antibody of CD20 acting on B cell epitopes, has been applied to the field of kidney since 2005, and has become a research hotspot in the clinical treatment of glomerulonephritis. At present, in addition to its clinical safety and efficacy, some researchers are still committed to explore the mechanism of RTX in the treatment of renal diseases, trying to find out whether there is a specific target in renal tissue. In this paper, the mechanism of RTX in the treatment of focal segmental glomerulosclerosis is reviewed.
